Skip to content
Clinical Trials – home
Recruiting

Comparison of General Anesthesia versus High-Flow Nasal Cannula Sedation in Patients with Acute Ischemic Stroke Undergoing Endovascular Treatment

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with acute ischemic stroke, a condition where blood flow to part of the brain is blocked. The research compares two different approaches during a procedure called mechanical thrombectomy, which removes blood clots from brain vessels. One approach uses general anesthesia, while the other uses sedation with a high-flow nasal cannula (a device that delivers oxygen through the nose).

The medications used in the study include lidocaine (a local anesthetic), fentanyl (a pain medication), propofol (an anesthetic medication), rocuronium bromide (a muscle relaxant), and medical oxygen. These medications are given through a vein, except for oxygen which is inhaled. The study aims to determine which approach leads to faster treatment times from hospital arrival to blood flow restoration in the brain.

During the study, patients will receive either general anesthesia with the mentioned medications or sedation with oxygen through a high-flow nasal cannula while doctors perform the clot removal procedure. The doctors will monitor how quickly they can complete the treatment and track the patient's recovery over time. They will also watch for any complications that might occur during or after the procedure.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial medical evaluation

    Your condition will be assessed as acute ischemic stroke, which is a type of stroke caused by a blood clot in the brain.

    Medical staff will evaluate if you meet the criteria, including being at least 18 years old and having specific stroke symptoms.

    The treatment must begin within 6 hours from when symptoms started, or within 24 hours if the last time you were seen without symptoms is known.

  2. Step 2

    Treatment group assignment

    You will be assigned to one of two treatment groups:

    Group 1: Treatment with general anesthesia

    Group 2: Treatment with sedation and high-flow nasal oxygen

  3. Step 3

    Medical procedure

    The medical team will perform a mechanical thrombectomy (procedure to remove the blood clot).

    If you are in the general anesthesia group, you will receive these medications through an IV line:

    - Propofol to induce sleep

    - Fentanyl for pain control

    - Lidocaine for local pain relief

    - Rocuronium for muscle relaxation

    If you are in the sedation group, you will receive oxygen through a nasal cannula

  4. Step 4

    Follow-up evaluations

    After 24 hours: Your condition will be evaluated using a special scale that measures stroke symptoms

    The medical team will check for any complications that might have occurred during or after the procedure

    After 90 days: Your recovery progress will be assessed using another scale that measures daily function abilities

  5. Step 5

    Study completion

    The study will track your progress until the final evaluation at 90 days

    Your participation will help determine which method leads to faster treatment times for stroke patients

Who can join the trial?

8 criteria

  • Must be 18 years of age or older
  • Must have a stroke severity score (NIHSS) between 6 and 25 points (NIHSS is a scale used by healthcare providers to measure the severity of a stroke)
  • Must have a stroke affecting the front part of the brain with blockage in either:
    • The internal carotid artery inside the skull (a major blood vessel that supplies blood to the brain)
    • The middle cerebral artery in specific segments called M1 or M2 (branches of blood vessels that supply blood to important areas of the brain)
    • Must arrive at the radiology department either:
      • Within 6 hours of when stroke symptoms first started, or
      • Within 24 hours of when the person was last seen without symptoms, if brain scans show there is brain tissue that can be saved
      • Must provide informed consent - either:
        • Signed by the patient if they are able to do so
        • Signed by a family member or legal representative if the patient is unable to consent

Who cannot join the trial?

15 criteria

  • Age below 18 or above 85 years old
  • Severe breathing problems or need for immediate airway support
  • Known allergies to anesthetic medications
  • Previous stroke in the past 3 months
  • Uncontrolled high blood pressure (blood pressure above 185/110 mmHg)
  • Active bleeding anywhere in the body
  • Blood sugar level below 50 mg/dL or above 400 mg/dL
  • Pregnancy or breastfeeding
  • Severe heart problems, including recent heart attack or unstable heart rhythm
  • Unable to give informed consent and no legally authorized representative available
  • Participation in another clinical trial within the last 30 days
  • Current treatment with blood thinners that cannot be reversed
  • Signs of bleeding in the brain on initial brain scan
  • Life expectancy less than 6 months due to other medical conditions
  • History of severe reaction to contrast dye used in medical imaging
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

General anesthesia is a type of anesthesia that puts you into a deep sleep during a medical procedure. During general anesthesia, you are completely unconscious and cannot feel pain. It is administered through inhaled gases or intravenous medications. High-flow nasal cannula (HFNC) is a respiratory support device that delivers warm, humidified oxygen through small tubes placed in your nostrils. It provides comfortable breathing support while keeping you awake and alert. This method is less invasive than general anesthesia and allows you to remain conscious during the procedure. Both methods are used during mechanical thrombectomy, which is a procedure to remove blood clots in patients with acute ischemic stroke.

What is already known about the treatment

Since this clinical trial compares two different approaches (general anesthesia and high-flow nasal cannula sedation), I'll describe both: General Anesthesia - A controlled state of unconsciousness administered through inhalation or intravenous medications, which provides complete immobility and pain control during medical procedures. This method involves placing a breathing tube and using specialized medications to maintain a deep state of sedation, commonly used in major surgical procedures including stroke interventions. General anesthesia works by affecting the central nervous system through multiple receptor systems, primarily GABA receptors, and belongs to the class of central nervous system depressants. High-Flow Nasal Cannula (HFNC) - A non-invasive oxygen delivery system that provides warmed and humidified oxygen through specialized nasal prongs at high flow rates, allowing conscious sedation during medical procedures. This device delivers oxygen more effectively than traditional nasal cannulas while maintaining patient comfort and awareness, and is increasingly used in various medical procedures including stroke interventions. HFNC works by providing positive airway pressure and improved oxygenation while reducing the work of breathing, and belongs to the class of respiratory support devices.

Investigated diseases

Acute Ischemic Stroke - A condition that occurs when blood flow to an area of the brain is blocked by a blood clot, preventing oxygen and nutrients from reaching brain tissue. It develops suddenly when an artery supplying blood to the brain becomes blocked, typically by a clot that has formed either at the site of blockage or elsewhere in the body and traveled to the brain. The affected brain tissue begins to die within minutes of oxygen deprivation, causing various symptoms depending on which area of the brain is affected. Common signs include sudden weakness or numbness on one side of the body, difficulty speaking or understanding speech, vision problems, and balance difficulties.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-510752-12-00Protocol codeGHIFTSEstimated enrolment116 patientsSponsorHospital Universitario La Paz

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).